Fertility Clinic for Sale: What Buyers Need to Know

The Fertility Clinic Acquisition Market in 2026

Fertility clinic acquisitions are a distinct subset of the healthcare M&A market — higher deal complexity, higher regulatory scrutiny, and higher valuations than most outpatient clinic categories. Understanding the market structure is the prerequisite to finding and evaluating any specific opportunity.

**PE consolidation has transformed the landscape.** Private equity-backed fertility platforms — CCRM, Inception Fertility, US Fertility, and others — have been actively acquiring independent fertility clinics for the past decade. These platforms have acquired many of the largest independent clinics, leaving the remaining independent market concentrated in smaller single-physician practices and regional clinics that have not yet received acquisition interest.

**The remaining independent market is the opportunity.** Single-location clinics generating $500K–$2M in EBITDA are below the minimum acquisition threshold for most PE platforms (which target $2M+ EBITDA deals) and are too complex for most individual buyers who lack clinical backgrounds. This creates a segment of well-run clinics with motivated owners and no obvious buyer pool.

**Demographics are driving demand.** IVF cycle volume in the US has grown at approximately 6–8% annually for the past decade, driven by delayed childbearing, greater insurance coverage for infertility treatment in a growing number of states, and increasing LGBTQ+ family formation. The patient demand side of the market is structurally growing regardless of economic cycles.

**Buyer profile matters significantly.** Fertility clinic acquisitions are not accessible to non-physician individual buyers in most states. The clinical entity must be owned by a licensed physician — typically a reproductive endocrinologist (REI) or OB-GYN — due to corporate practice of medicine laws. Non-physician buyers typically structure acquisitions through a physician-partner arrangement or Management Services Organization (MSO). This significantly narrows the realistic buyer pool.

For the broader fertility sector market context, the fertility clinic acquisition guide covers deal structures, buyer profiles, and what institutional buyers look for.

Fertility Clinic Valuation: What These Clinics Are Worth

Fertility clinics are valued on EBITDA multiples, with the multiple range driven by IVF cycle volume, success rates, physician depth, and geographic market characteristics. The EBITDA multiple range for fertility clinics is **4.5–8.0x**, wider than most outpatient clinic categories because the spread between a high-volume, multi-physician clinic and a single-physician practice is dramatic.

**IVF cycle volume is the primary value driver.** A clinic completing 400+ IVF cycles per year at $15,000–$25,000 per cycle has a revenue base that scales efficiently with physician and lab capacity. A clinic completing 80 cycles per year is a different business. Volume drives margin leverage on fixed embryology lab costs and positions the clinic for PE platform interest.

**Embryology lab quality and success rates.** SART-reported live birth rates are public. A clinic whose reported success rates are above the national average for its patient age demographic commands a premium — both because outcomes justify premium pricing and because success rates are genuine moats against competitive entry. Buyers should review 5 years of SART data before making any offer.

**Physician depth and succession.** A clinic where a single founder physician performs 90% of retrievals and transfers is a key-man risk that meaningfully discounts the multiple. A clinic with two or three board-certified REIs sharing caseload is a business that can survive a physician departure. Each additional credentialed physician who is not the selling founder reduces the key-man discount.

**Ancillary revenue streams.** Egg banking, sperm banking, embryo storage, preimplantation genetic testing (PGT), and donor egg programs generate revenue that diversifies beyond fresh IVF cycles and often carries higher margins. A clinic with a robust egg bank generates recurring storage revenue that is not tied to new patient cycle volume.

Run adjusted EBITDA against healthcare specialty services multiples in the EBITDA Valuation Estimator before making any offer.

• Multi-physician, 400+ IVF cycles, above-average success rates, ancillary programs: 6.5–8.0x EBITDA
• 2 physicians, 200–400 cycles, strong outcomes, growing market: 5.5–6.5x EBITDA
• Founder-physician, 100–200 cycles, good outcomes, established patient base: 4.5–5.5x EBITDA
• Single physician, under 100 cycles, limited ancillary: 3.5–4.5x EBITDA

Regulatory and Licensing Complexity

Fertility clinic acquisitions involve a regulatory complexity that exceeds most outpatient healthcare acquisitions. Buyers who underestimate this component create legal and operational risk that can be existential.

**Corporate practice of medicine.** Every state restricts or prohibits lay ownership of medical practices. For fertility clinics, which are physician-directed medical practices, the clinical entity must be owned by a licensed physician. Non-physician buyers must structure through an MSO framework — the physician partner owns the clinical PC or PLLC, the buyer owns the management services entity. This framework is well-understood by healthcare attorneys but requires careful drafting and a physician partnership structure that is both legally sound and economically fair to both parties.

**CLIA certification.** Every fertility clinic operating an embryology lab must hold Clinical Laboratory Improvement Amendments (CLIA) certification from CMS. CLIA certificates are issued to specific laboratory directors at specific physical locations. A change of ownership requires notification to CMS and may require reapplication for CLIA certification. The laboratory director (typically a PhD embryologist) who holds the CLIA certification must remain in place through the transition, or a qualified replacement must be designated and approved.

**State-specific ART regulations.** Several states have enacted regulations specific to assisted reproductive technology — rules around gamete consent, embryo disposition, donor anonymity, gestational carrier agreements, and related matters. Some of these create liability that follows the clinical entity. A healthcare attorney with ART-specific experience should review state law before close.

**FDA oversight.** Fertility clinics using donor gametes or performing PGT are subject to FDA regulation under the Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P) rules. Confirm that the clinic's donor screening, processing, and storage procedures meet current FDA requirements and that FDA inspection history is clean.

**SART membership and accreditation.** Society for Assisted Reproductive Technology membership and accreditation status are de facto prerequisites for insurance reimbursement and patient confidence. Confirm membership is current, accreditation is in good standing, and there are no pending compliance actions.

Financing a Fertility Clinic Acquisition

Fertility clinic acquisitions in the $1M–$5M range occupy a financing middle ground: too large for standard SBA 7(a) terms on many deals, too small for PE-backed acquisition finance. The most common structures:

**SBA 7(a) for smaller transactions.** Clinics generating $200K–$500K in EBITDA at acquisition prices of $1M–$2.5M are within SBA 7(a) parameters. The standard 10% equity injection, 10-year term, and prime-plus spread applies. CLIA certification, physician employment agreements, and SART status are elements that SBA lenders in the healthcare sector will want to verify before approval.

**Conventional healthcare lending for larger transactions.** Clinics generating $500K+ in EBITDA often require conventional healthcare lending — term loans from banks with active healthcare portfolios, at 4.5–6.5x leverage depending on cash flow quality. These lenders underwrite physician employment/retention as a key variable.

**PE platform acquisition or partnership.** If you are a physician looking to monetize a well-built clinic while maintaining clinical leadership, a PE platform acquisition — where you sell a majority interest and stay on as a clinical partner — may be more appropriate than a traditional sale. CCRM, Inception Fertility, and US Fertility all have active acquisition programs. The economic structure in these transactions is typically a combination of upfront cash, rollover equity, and performance earnouts tied to EBITDA growth.

**Physician partner equity.** In non-physician buyer transactions using the MSO structure, the physician partner typically receives an equity stake in the clinical entity in exchange for their medical directorship role. Structuring this correctly — so that the physician partner's economic interest aligns with the business's success without creating regulatory risk — requires careful legal drafting.

Model any deal before approaching lenders. The SBA Loan Calculator shows your monthly payment, DSCR, and whether the clinic's EBITDA supports your target price at current rates.

Due Diligence Priorities for Fertility Clinic Acquisitions

Fertility clinic due diligence is more intensive than typical outpatient clinic acquisition due diligence. The items that matter most and are most commonly underweighted:

**Review SART outcome data for the last 5 years.** SART reports are public. Pull the clinic's reported data and compare to national averages by patient age category. A sustained above-average live birth rate is a genuine asset. A below-average rate or a pattern of declining outcomes is a clinical quality signal that affects both valuation and patient retention.

**Audit embryology lab compliance and CLIA inspection history.** Request the last three CLIA inspection reports and any deficiency notices. A history of CLIA deficiencies — particularly those involving embryology lab quality control, temperature monitoring, or chain-of-custody procedures — is material. These are not easily or quickly remediated.

**Review physician employment agreements.** The clinical value of the acquisition is tied to the physicians. What are their contract terms? Do they have non-compete provisions? What are the conditions for departure? A physician whose employment agreement expires at close is a retention risk that must be addressed before you commit to a price.

**Verify insurance contracts and authorization processes.** Fertility treatments have expanded insurance coverage in many states. A clinic that is in-network with major commercial plans and has established prior authorization processes has a patient acquisition advantage that an out-of-network clinic lacks. Confirm the in-network status with each payer and understand the reimbursement rates.

**Assess cryostorage obligations.** Fertility clinics hold frozen embryos, eggs, and sperm belonging to patients — some of whom may have been storage clients for years or decades. The legal and logistical obligations associated with cryostorage are significant. Confirm the storage consent and fee structures, the condition and age of storage equipment, and whether there are any pending disputes about stored material.

For the broader healthcare due diligence framework, the healthcare business acquisition due diligence checklist covers billing compliance, licensing, and regulatory review applicable across healthcare practice acquisitions.

How to Find a Fertility Clinic for Sale

Fertility clinic deal flow is concentrated in a few channels. General business broker platforms are largely irrelevant — the deal type requires specialized advisors.

**Healthcare M&A advisors specializing in reproductive medicine.** A small number of boutique healthcare M&A firms have active fertility clinic practices — firms like Healthcare M&A Partners, Merritt Hawkins (part of AMN Healthcare), and specialty advisors who work exclusively in reproductive medicine. These firms have relationships with retiring founders before they formally list.

**PE platform outreach.** If you are a physician with an established clinic considering a sale, the PE platforms will find you — particularly if your volume exceeds 150 cycles per year. Reviewing their publicly available acquisition criteria and responding to outreach is a starting point. Having your own advisor in these conversations is not optional.

**ASRM and SART networks.** The American Society for Reproductive Medicine annual meeting and SART membership networks are where retiring clinic founders discuss succession. Relationship-based networking within these professional communities surfaces pre-market opportunities that never become public listings.

**Direct outreach.** For buyers with the clinical credentials and financing credibility to be taken seriously, a direct letter to owner-physicians at clinics with known succession questions (long-tenured single physician with no associates) can surface conversations. The outreach must be specific, informed, and credible — a generic inquiry will be ignored.

When a conversation advances to serious terms, the LOI Generator produces a professional Letter of Intent — including CLIA transfer provisions, physician retention requirements, SART compliance contingency, and financing terms — in under two minutes.